1. The comorbidity statistics: ADHD does not travel alone
If a single point can anchor everything else on this page, it is this: comorbidity is the rule, not the exception, in ADHD. Across population-based samples, between 60% and 80% of children and adults with ADHD meet criteria for at least one additional psychiatric condition over the course of their lifetime. This is the highest comorbidity rate in psychiatry. It exceeds the comorbidity rates of major depression, generalized anxiety disorder, and even autism spectrum disorder.
The evidence comes from multiple converging sources:
The National Comorbidity Survey Adolescent Supplement (NCS-A)
Our 2021 analysis of the NCS-A - a nationally representative U.S. sample of 6,483 adolescents aged 13-18 with structured diagnostic interviews - found that 69.5% of adolescents with ADHD had at least one comorbid mental health condition, compared with 40.8% of adolescents without ADHD (Sultan et al., J Adolesc Health). The elevated rate spanned mood disorders, anxiety disorders, disruptive behavior disorders, and substance use disorders. The implication for clinical practice is direct: when you see an adolescent with ADHD, you should expect at least one additional diagnosis to be present, and you should screen for it actively.
The MTA Study
The Multimodal Treatment of ADHD Study (MTA) recruited 579 children with carefully diagnosed ADHD, combined type. Jensen and colleagues (2001) reported that fewer than one-third had ADHD alone: 31% had no comorbidity, 40% had one comorbid disorder, 14% had two, and 14% had three or more. The most common comorbidities were oppositional defiant disorder (40%), anxiety disorders (34%), and conduct disorder (14%). This was a clinical trial sample, not a population sample, so the rates may be inflated by referral bias - but the pattern is consistent with everything that has followed.
The National Comorbidity Survey Replication (NCS-R adult sample)
Kessler and colleagues (2006), in the foundational NCS-R adult ADHD analysis, found that adults with ADHD had significantly elevated lifetime odds of mood disorders (OR 2.7-7.5), anxiety disorders (OR 2.9-5.3), and substance use disorders (OR 1.5-7.9). Among adults with current ADHD, more than half met criteria for at least one comorbid mood, anxiety, or substance use disorder in the prior 12 months.
Danish and Swedish national registry data
The Scandinavian registries provide the highest-quality population data in the world, linking psychiatric, medical, educational, and criminal records across entire national populations. The Dalsgaard cohort (Lancet 2015, N=1.92 million) and the Swedish national registry studies (Lichtenstein, Larsson, Chang) consistently show 2-3 fold elevations in comorbid psychiatric diagnoses among individuals with ADHD across the lifespan. These data are not vulnerable to referral bias - they capture everyone in the country - and they replicate the U.S. findings.
2. The two-question framework for any given symptom
For any symptom a patient reports - inattention, restlessness, irritability, poor sleep, low motivation, emotional dysregulation - a comorbidity-aware clinician asks three questions in sequence:
- Is this from ADHD? Is the symptom explainable by core ADHD features (inattention, impulsivity, hyperactivity, executive dysfunction, emotional dysregulation) operating in the patient's developmental and environmental context?
- Is this from a separate condition? Could the same symptom be explained by an anxiety disorder, mood disorder, sleep disorder, substance use, medical condition, or stressor?
- Is this from both, interacting? Is the symptom present at baseline from ADHD but worsened by, or worsening, a co-occurring condition?
The third question is the one most often skipped, and it is the one that drives the most consequential clinical decisions. A patient whose anxiety is worsened by chronic ADHD-related life stress will not get well from SSRI monotherapy if the ADHD goes untreated. A patient whose ADHD-like attention failure is actually driven by untreated obstructive sleep apnea will not benefit from stimulants if the OSA is missed. The framework forces the clinician to consider that more than one mechanism can be operating simultaneously.
The corollary is that "comorbid" and "confounded" are not the same thing:
| Pattern | Meaning | Clinical implication |
|---|---|---|
| Comorbid | Two genuine conditions present in the same person. Both meet criteria. Both produce impairment. | Both require treatment, usually sequenced by acuity and dangerousness. |
| Confounded | One condition is mimicking another. Only one condition is actually present; the second "diagnosis" is an artifact. | Treat the actual condition; the "second diagnosis" resolves. |
| Interacting | Two conditions present, but one is meaningfully worsening the other. | Both require treatment; order matters more than usual. |
The clinical examples that follow are organized by comorbid condition, but the framework above governs how to think about each one.
3. Anxiety and ADHD
Co-occurrence: 25-50% in both pediatric and adult samples. Anxiety is the single most common psychiatric comorbidity in ADHD across the lifespan.
Why they co-occur
ADHD and anxiety share genetic liability (twin studies show overlapping heritability), but most of the co-occurrence in clinical practice is driven by the chronic functional stress of living with untreated or under-treated ADHD: missed deadlines, social rejection, academic underperformance, financial chaos, and the cumulative experience of failing at things that other people manage easily. By adulthood, this "second-order" anxiety often meets criteria for generalized anxiety disorder, social anxiety disorder, or panic disorder.
How to tell anxiety from ADHD-driven inattention
The two conditions overlap on restlessness, distractibility, difficulty concentrating, and sleep disturbance. Distinguishing features:
| Feature | ADHD attention failure | Anxiety attention failure |
|---|---|---|
| Developmental course | Lifelong, by definition before age 12 | May emerge at any age; often tied to specific stressor |
| What drives the distraction | Attention drifts to whatever is more interesting | Attention narrows onto threat or worry content |
| Presence in low-demand settings | Often still present (hobbies, games, conversations) | Often absent in genuinely low-stress moments |
| Subjective experience | "My mind goes everywhere" | "My mind keeps going back to the thing I'm worried about" |
| Hyperactivity quality | Constant, unfocused motor restlessness | Tension-driven, often situational |
Treatment ordering
For mild-to-moderate anxiety plus ADHD, the typical sequence is to begin with an SSRI (sertraline or escitalopram are first-line for most anxiety presentations) and observe whether residual attention problems require ADHD-specific treatment. For severe ADHD with secondary anxiety, treating the ADHD first often resolves the anxiety. For severe panic disorder or OCD-spectrum anxiety, the anxiety usually takes precedence. Stimulants can worsen anxiety in a minority of patients - typically those with pre-existing severe anxiety - which is one reason guanfacine, atomoxetine, or viloxazine are sometimes preferred when anxiety and ADHD co-occur.
For deeper discussion, see the dedicated spokes: ADHD vs Anxiety and The ADHD-Anxiety Connection.
4. Depression and ADHD
Lifetime co-occurrence: 20-40%. The risk ratio for major depressive disorder is approximately 2.7-fold elevated in adults with ADHD (Kessler 2006, NCS-R).
Why the elevated risk
The mechanism is partly shared genetic liability and partly the cumulative weight of untreated functional impairment. Adolescents with untreated ADHD experience repeated academic and social failure, which feeds learned helplessness, demoralization, and ultimately full-syndrome depression. Adults with untreated ADHD experience the same cascade at work and in relationships. Suicidal ideation and suicide attempts are substantially elevated in ADHD: in our NCS-A analysis, adolescents with ADHD had 2.9-fold higher adjusted odds of suicide attempts and 23.1% reported suicidal thoughts versus 11.0% of peers (Sultan 2021).
Distinguishing ADHD-related demoralization from MDD
This is one of the most clinically important distinctions in adult psychiatry. ADHD-related demoralization is reactive, situational, and lifts when functional success returns. Major depressive disorder is autonomous - it persists even when external circumstances improve - and it carries the full neurovegetative syndrome: anhedonia, sleep disturbance with characteristic early-morning awakening, appetite change, psychomotor slowing or agitation, worthlessness, and impaired concentration that is distinguishable from baseline ADHD inattention.
| Feature | ADHD demoralization | Major depressive disorder |
|---|---|---|
| Mood quality | Frustrated, defeated, self-critical about specific failures | Pervasive sadness, hopelessness, anhedonia |
| Course | Lifts when success returns or environment improves | Autonomous; persists for weeks despite circumstance changes |
| Sleep | Often delayed sleep phase, fragmented | Early-morning awakening typical in melancholic MDD |
| Anhedonia | Preserved enjoyment of high-stimulation activities | Loss of enjoyment across all activities |
| Cognitive symptoms | Lifelong baseline inattention; impulsivity | Acute change in concentration during episode |
Treatment ordering
For moderate-to-severe MDD plus ADHD, the typical sequence is to stabilize the depression first (SSRI or SNRI plus psychotherapy) and then add ADHD pharmacotherapy for residual inattention and executive dysfunction. Bupropion is the antidepressant with the most evidence for both depression and modest ADHD efficacy and is a reasonable choice when both diagnoses are present. Stimulants alone are not approved for MDD. For severe ADHD with secondary mood symptoms that have not yet crossed into full MDD, treating ADHD first often produces rapid mood improvement.
For deeper discussion, see Depression vs ADHD: Distinguishing the Two.
5. Autism Spectrum Disorder and ADHD
Co-occurrence: 15-25% of pediatric ADHD samples meet criteria for ASD; 30-80% of pediatric autism samples meet criteria for ADHD. The Leitner 2014 review summarized the evidence base.
The DSM-5 change
Before DSM-5 (published 2013), the two diagnoses could not be co-diagnosed: autism ruled out ADHD and vice versa. This was a clinical fiction maintained for nosological convenience, not because the conditions were mutually exclusive. DSM-5 explicitly allows dual diagnosis. This change was driven by decades of evidence that:
- The two conditions share substantial genetic liability (twin studies, polygenic risk scores)
- The two conditions share neurodevelopmental mechanisms (executive function deficits, sensory processing differences)
- Children with both conditions have measurably worse functional outcomes than children with either alone
- Each condition requires its own treatment plan; the second diagnosis is not redundant
How they look together
Dual-diagnosed children typically present with:
- Social communication differences from autism that are amplified by impulsivity and inattention from ADHD
- Restricted, repetitive interests that can be misread as ADHD hyperfocus, and ADHD hyperfocus that can be misread as autism perseveration
- Sensory hypersensitivity or hyposensitivity that interacts with ADHD-related sensory seeking
- Executive function impairment that is more severe than either disorder alone
- Emotional dysregulation that is substantially worse than either alone, particularly meltdowns
Treatment implications
ADHD pharmacotherapy works in dual-diagnosed patients but is somewhat less effective and somewhat more likely to produce side effects than in ADHD alone. Methylphenidate response rates in autism plus ADHD are approximately 50-65%, compared with 75-85% in ADHD alone (RUPP Autism Network trials). Behavioral interventions targeting both diagnoses - social skills training, sensory integration, parent training adapted for autism - are essential adjuncts.
For deeper discussion, see ADHD vs Autism: Differential Diagnosis.
6. OCD and ADHD
Co-occurrence: 10-15%. Lower than the conditions above, but treatment-relevant because the medications for OCD and ADHD interact in complex ways.
The diagnostic challenge
OCD and ADHD share inattention, mental restlessness, and difficulty completing tasks - but the mechanisms are very different. In OCD, attention fails because intrusive thoughts and compulsions hijack working memory. In ADHD, attention fails because of underlying executive dysfunction. A patient with OCD may appear to have ADHD when in reality the inattention is a downstream consequence of obsessions.
Distinguishing features:
- Content of distraction: OCD distractions are ego-dystonic intrusive thoughts and compulsive urges; ADHD distractions are typically more rewarding or interesting stimuli
- Effort to resist: OCD patients typically experience compulsions as unwanted and effortful to resist; ADHD impulses are more often acted on without resistance
- Insight: OCD typically includes recognition that the thoughts are excessive; ADHD does not involve the same insight structure
Treatment complexity
SSRIs are first-line for OCD and are typically dosed higher than for depression (fluoxetine 60-80 mg, sertraline 200 mg). Stimulants can theoretically worsen OCD-related rumination, but in practice the more common pattern is that treating ADHD improves OCD-related task incompletion. The order is typically: stabilize OCD first with an SSRI at OCD-doses plus exposure and response prevention therapy, then treat residual ADHD. Both conditions can be treated simultaneously, but careful titration is required.
For deeper discussion, see OCD and ADHD: Comorbidity and Treatment.
7. Sleep apnea and ADHD
Co-occurrence: approximately 33%. Sleep problems of all kinds occur in 70% or more of children and adults with ADHD; obstructive sleep apnea (OSA) is the single most clinically important sleep comorbidity because it both co-occurs with ADHD and mimics ADHD.
Why OSA matters here
OSA fragments sleep through repeated micro-arousals as the airway collapses and the patient briefly wakes to resume breathing. The result is non-restorative sleep, daytime sleepiness, and - especially in children - paradoxical hyperactivity, inattention, and behavioral dysregulation that is clinically indistinguishable from ADHD. A meaningful subset of children referred for ADHD evaluation turn out to have OSA, and treatment of the OSA (typically adenotonsillectomy in children) substantially reduces or eliminates the apparent ADHD symptoms.
Screening
Every ADHD evaluation should include screening for sleep pathology. The minimum screen is:
- Snoring (frequency, loudness, observed by partner or parent)
- Witnessed apneic pauses
- Mouth breathing (especially in children with adenotonsillar hypertrophy)
- Morning headaches
- Restless sleep with frequent position changes
- Daytime sleepiness (in adults; in children, often hyperactivity)
- In adults: neck circumference, body habitus, history of hypertension
Positive screens warrant polysomnography. Empirically treating with stimulants in the face of unaddressed OSA is a common error and a missed opportunity for definitive treatment.
For deeper discussion, see ADHD vs Sleep Apnea and the broader ADHD and Sleep overview.
8. Bipolar disorder and ADHD: the misdiagnosis risk in both directions
The bipolar-ADHD distinction is one of the most consequential differential diagnoses in psychiatry. Misdiagnosis goes both ways and the treatment implications are large.
The overlap
ADHD and bipolar disorder both feature distractibility, impulsivity, restlessness, decreased need for sleep, and rapid speech. In pediatric populations, the differential is particularly fraught: irritability and emotional dysregulation are core features of ADHD but were historically and still sometimes misread as pediatric mania.
The distinguishing features
| Feature | ADHD | Bipolar mania/hypomania |
|---|---|---|
| Course | Chronic, present from childhood, day-to-day stable | Episodic, with discrete periods of mood elevation |
| Sleep | Difficulty falling asleep but typically tired the next day | Decreased need for sleep (alert and energized on 3-4 hours) |
| Mood elevation | Not present as a discrete state | Sustained euphoria or expansiveness, often grandiosity |
| Speech | Talkative, off-topic, but coherent | Pressured, hard to interrupt, often flight of ideas |
| Goal-directed activity | Often fragmented, scattered, started but unfinished | Intense, sustained, often unrealistic (writing a novel in three days) |
| Family history | Family history of ADHD common | Family history of bipolar I disorder strongly suggestive |
| Course of impulsivity | Chronic, baseline | Episodic, with discrete periods of high-risk behavior |
The treatment stakes
Misdiagnosing bipolar disorder as ADHD and prescribing a stimulant can precipitate or worsen mania, especially in patients with bipolar I disorder. Misdiagnosing ADHD as bipolar disorder and starting a mood stabilizer or antipsychotic exposes the patient to substantial metabolic, sedative, and tardive dyskinesia risk for a condition they do not have. In comorbid bipolar plus ADHD - which is real, with co-occurrence rates of approximately 10-15% - the standard sequence is to stabilize the mood disorder first with a mood stabilizer (lithium, divalproex, lamotrigine) or atypical antipsychotic, and then add a stimulant cautiously for residual ADHD symptoms, with careful monitoring for mood destabilization.
9. PTSD, trauma, and ADHD: the differential and the sequencing of care
PTSD and ADHD overlap substantially. Inattention, hypervigilance, irritability, sleep disturbance, and emotional dysregulation appear in both. Distinguishing them - and recognizing when both are present - is a core skill in trauma-aware ADHD assessment.
Overlapping features
- Concentration difficulty: PTSD-related concentration failure is driven by intrusive memories and hypervigilance; ADHD concentration failure is baseline executive dysfunction.
- Sleep disturbance: PTSD sleep problems are typically nightmares and trauma-related awakenings; ADHD sleep problems are typically delayed sleep phase and difficulty falling asleep.
- Irritability and emotional dysregulation: Both produce reactive emotional outbursts; PTSD outbursts are typically tied to trauma cues; ADHD outbursts are typically tied to frustration and demand.
- Hyperactivity vs hypervigilance: ADHD restlessness is motor and unfocused; PTSD hypervigilance is sensory and threat-focused.
The clinical task
A trauma history should be screened in every ADHD evaluation, particularly when the apparent ADHD symptoms emerged after age 12, when there is a documented adverse childhood experiences history, or when the patient's attention failure is paired with prominent hypervigilance, exaggerated startle, or trauma-specific avoidance. In genuine comorbidity, trauma-focused therapy (CPT, PE, EMDR) is layered with ADHD pharmacotherapy. In children, the recognition that complex trauma can mimic ADHD - or co-occur with it - has substantially changed how careful evaluations are conducted.
Treatment sequencing
Severe untreated PTSD typically takes precedence over ADHD treatment, because trauma-focused therapy requires the cognitive and emotional bandwidth to engage with trauma material. However, severe ADHD that prevents engagement with trauma therapy is sometimes treated first to allow PTSD treatment to proceed. The decision is clinical, not algorithmic.
10. Learning disorders and ADHD
Co-occurrence: 30-50%. Specific learning disorders - most commonly dyslexia (specific learning disorder with impairment in reading) and dyscalculia (specific learning disorder with impairment in mathematics) - co-occur with ADHD at rates substantially higher than chance.
Why they co-occur
The two share neurodevelopmental etiologies and overlapping genetic liability. Both emerge early in development and become apparent when academic demand exceeds the child's capacity. The cognitive substrates differ - ADHD primarily involves executive function and attention regulation; dyslexia primarily involves phonological processing; dyscalculia primarily involves numerical magnitude representation - but the conditions interact functionally because all three impair academic performance.
The treatment trap
Treating ADHD does not fix a learning disorder. ADHD pharmacotherapy improves sustained attention to academic tasks, which helps a student get more out of evidence-based educational intervention. But it does not remediate the phonological deficit in dyslexia or the numerical cognition deficit in dyscalculia. A child with both ADHD and dyslexia who is started on a stimulant will show improved on-task behavior but will still struggle with reading until structured literacy instruction is provided. Parents and teachers sometimes interpret persistent reading struggle on stimulant therapy as treatment failure when in reality the stimulant is doing exactly what it is supposed to do and the LD remains untreated.
What treatment looks like together
- ADHD pharmacotherapy for the attention and executive function deficits
- Structured literacy (Orton-Gillingham approach) for dyslexia
- Explicit, multisensory math instruction for dyscalculia
- Educational accommodations (extended time, alternative format testing, note-taking support)
- 504 plan or IEP to formalize school-based supports
11. Substance use disorders and ADHD: bidirectional risk
Co-occurrence: elevated 1.5-2.6x for most substances. In our NCS-A analysis, adolescents with ADHD had 1.9x higher odds of alcohol use problems, 2.2x higher odds of cannabis use, 2.6x higher odds of cocaine use, and 2.6x higher odds of non-prescribed prescription drug use (Sultan 2021). The Wilens 10-year follow-up of young adults with childhood ADHD found substantially elevated rates of substance use disorder.
The bidirectional relationship
ADHD elevates SUD risk through impulsivity, self-medication, and the cumulative social and academic failure of untreated ADHD. SUDs in turn worsen apparent ADHD symptoms through direct cognitive effects, sleep disruption, and the lifestyle chaos of active addiction. Sorting out which is primary - especially in adolescents and young adults presenting with both - is difficult and often requires a period of sobriety to clarify the baseline ADHD picture.
The cannabis-ADHD link
Cannabis is the substance most commonly used by adolescents with ADHD. The bidirectional risk is substantial: ADHD elevates cannabis use risk, and cannabis use - particularly heavy adolescent use - is associated with worse executive function, worse academic outcomes, and elevated risk for psychosis. For deeper discussion, see Cannabis and ADHD: The Risk Profile.
Medication safety in SUD recovery
The historical concern that stimulant treatment of ADHD would increase later SUD risk has been largely refuted by within-individual analyses showing that medication treatment is associated with lower, not higher, substance use rates. Quinn and colleagues (2017) demonstrated 31-35% lower substance-related emergency events during medicated months in a 2.99 million-patient MarketScan analysis. In active SUD recovery, the choice of ADHD medication should be made with the patient's recovery program: non-stimulants (atomoxetine, guanfacine, viloxazine) and long-acting stimulants with low abuse liability (lisdexamfetamine) are generally preferred over short-acting immediate-release stimulants.
For deeper discussion, see ADHD and Substance Use.
12. Tic disorders and ADHD
Co-occurrence: 10-20% of children with ADHD have a tic disorder; approximately 50-60% of children with Tourette syndrome have ADHD.
The historical concern about stimulants
For decades, stimulant medications carried a warning that they could "cause or worsen tics," which led many clinicians to avoid stimulants in patients with comorbid tic disorders. Subsequent placebo-controlled trials, most notably the Treatment of ADHD in Children with Tics (TACT) trial, found that methylphenidate did not worsen tics on average and that the combination of methylphenidate plus clonidine was the most effective treatment for ADHD plus tics. The current evidence base supports stimulant use in ADHD plus tic disorder, with careful monitoring; a minority of patients do experience tic worsening and may need a non-stimulant alternative (guanfacine and clonidine treat both tics and ADHD).
For deeper discussion, see ADHD, Tic Disorders, Tourette, and Stimulants.
13. Eating disorders and ADHD
Co-occurrence: elevated 2-4x in women with ADHD. The ADHD-eating disorder link is particularly important in adolescent girls and adult women, who are at elevated risk for both binge eating disorder and restrictive eating patterns.
Mechanism
ADHD-related impulsivity, reward sensitivity, and emotional dysregulation contribute to binge eating. ADHD-related interoceptive insensitivity, time blindness, and chaotic daily structure contribute to under-eating and inadvertent restriction. ADHD-related self-criticism and demoralization feed body image concerns. The combination of stimulant-related appetite suppression with pre-existing restrictive tendencies requires careful monitoring in adolescent girls and adult women started on ADHD medication.
Treatment
Treatment of comorbid eating disorder plus ADHD requires both - eating disorder-focused therapy (typically CBT-E, FBT for adolescents, or DBT for binge eating) plus ADHD pharmacotherapy with appetite and weight monitoring. Lisdexamfetamine has an FDA indication for binge eating disorder, which makes it a useful choice in patients with this specific comorbidity.
For deeper discussion, see ADHD and Eating Disorders: Binge and Restrictive Patterns (sibling article being published in parallel).
14. What's NOT ADHD that often looks like it
The differential diagnosis of ADHD includes both psychiatric and medical conditions that mimic ADHD without being ADHD. A careful evaluation rules these out before - or alongside - making the diagnosis.
Medical mimics
| Condition | How it mimics ADHD | How to detect |
|---|---|---|
| Obstructive sleep apnea | Daytime inattention, hyperactivity (especially in children) | Snoring history, witnessed apneas, polysomnography |
| Hyperthyroidism | Restlessness, irritability, poor concentration, weight loss | TSH, free T4, T3 |
| Iron deficiency | Attention problems, restlessness, especially with restless legs syndrome | Ferritin (target >30 ng/mL), CBC |
| Hearing impairment | Apparent inattention, especially in classroom | Audiology screen |
| Vision problems | Apparent inattention to reading or board work | Vision screen |
| Lead exposure | Attention and behavior problems in young children | Blood lead level in at-risk children |
| Absence epilepsy | Brief lapses of attention misread as ADHD inattention | EEG when clinical suspicion is present |
Psychiatric and environmental mimics
- Severe psychosocial adversity: Chronic stress, food insecurity, housing instability, domestic conflict, and adverse childhood experiences can produce attention and behavior problems that look like ADHD but resolve when the stressor resolves.
- Trauma and PTSD: Hypervigilance and intrusive memory produce attention problems that overlap with ADHD.
- Generalized anxiety disorder: Worry-driven distractibility mimics ADHD inattention.
- Major depressive disorder: Acute concentration impairment from depression can be mistaken for ADHD, particularly in adults presenting for first evaluation in midlife.
- Substance use: Active cannabis, alcohol, or stimulant use can produce ADHD-like symptoms.
- Developmentally appropriate behavior: Particularly in young children, normal age-appropriate restlessness can be misread as ADHD.
15. The structured comorbidity-aware ADHD evaluation
A high-quality ADHD evaluation in 2026 is not a checklist of DSM-5 criteria. It is a structured assessment that holds comorbidity and differential diagnosis in view throughout. The order of assessment matters because what you find early shapes what you ask later.
Recommended order
- Developmental history: Symptom onset, timing of impairment, school history, medical milestones. Symptoms must have been present before age 12 for ADHD diagnosis (DSM-5).
- Current symptoms across settings: Inattention, impulsivity, hyperactivity, executive function, emotional dysregulation. Validated rating scales (Vanderbilt for children, ASRS or Conners for adults).
- Functional impairment: Academic, occupational, social, family, and self-management impairment. Diagnosis requires impairment, not just symptoms.
- Sleep history: Falling asleep, staying asleep, snoring, witnessed apneas, daytime sleepiness. Screen for OSA, delayed sleep phase, and chronic sleep restriction.
- Medical screen: Thyroid, iron, hearing, vision, lead (if at risk), seizures, head injury history.
- Mood and anxiety screen: PHQ-9, GAD-7, or equivalent. Lifetime mood episodes, current depressive or manic symptoms.
- Substance use screen: CAGE, AUDIT, drug use history with specific substances.
- Trauma screen: Adverse childhood experiences, current trauma exposure, PTSD symptoms.
- Family history: ADHD, autism, mood disorders, anxiety disorders, substance use, suicide.
- Cognitive and academic assessment: When learning disorder is suspected, neuropsychological testing.
- Collateral information: From a partner, parent, teacher, or longstanding friend - particularly important for adults presenting for first-time evaluation.
When to refer for specialty assessment
- Bipolar disorder differential unresolved - psychiatric specialty assessment
- Suspected autism spectrum disorder - autism-trained psychologist for ADOS-2
- Suspected learning disorder - neuropsychologist for cognitive and academic testing
- Suspected sleep disorder - sleep medicine for polysomnography
- Active substance use disorder - addiction psychiatry for integrated treatment
- Active trauma or complex PTSD - trauma-trained therapist
For deeper guidance on what a high-quality evaluation looks like, see the dedicated ADHD Topic Hub and the patient-facing Ask the Doctor page.
16. Treatment ordering principles: which condition to stabilize first
When two conditions are present, the order of treatment matters. The general principle is to stabilize the most acute or dangerous condition first, then layer in treatment for residual conditions.
Conditions that take precedence over ADHD treatment
- Active suicidality: Safety first. Mood disorder treatment, safety planning, and sometimes hospitalization precede ADHD treatment.
- Active mania or psychosis: Mood stabilization or antipsychotic treatment first. Stimulants can precipitate or worsen mania.
- Severe untreated MDD: Antidepressant treatment first. Residual ADHD treated after mood is stable.
- Active substance use disorder with acute medical risk: Detoxification and stabilization first. ADHD pharmacotherapy added in recovery with abuse-liability awareness.
- Severe untreated OSA: Sleep medicine evaluation and treatment first. Empiric stimulant therapy without OSA workup is an error.
- Severe untreated PTSD: Often trauma-focused therapy first, sometimes ADHD treatment first to allow trauma work to proceed.
Conditions where ADHD treatment is often started first
- Mild-to-moderate anxiety that appears driven by ADHD-related functional stress
- Mild-to-moderate demoralization not meeting full MDD criteria
- Comorbid learning disorder: ADHD treatment improves engagement with educational intervention
- Comorbid mild eating disorder: With careful weight and appetite monitoring
- Tic disorder: Stimulants do not worsen tics on average
The "and not or" principle
In nearly all comorbidity scenarios, both conditions ultimately require treatment. The question is sequence, not substitution. Treating only one of two comorbid conditions reliably produces partial response, which is often misread as treatment failure. The 69.5% comorbidity rate in our NCS-A analysis means that a clinician treating "pure" ADHD is the exception. Treatment planning that holds both - or all three, or all four - diagnoses in view is the norm in practice.
Read the companion pillars
Comorbidity is one of eight thematic clusters in this ADHD library. Treatment of the underlying ADHD draws on the pharmacology pillar, the lifestyle adjuncts pillar, and the natural-course pillar.
Pharmacology & Natural Course → Lifestyle Adjuncts → Untreated ADHD Outcomes →17. Frequently asked questions
Why does ADHD come with so many other conditions?
ADHD has the highest comorbidity rate in psychiatry because it is a developmental disorder of self-regulation that begins early in life and shapes nearly every domain of functioning. Each of the capacities ADHD impairs - attention, impulse control, working memory, emotional regulation - sits upstream of multiple other conditions. There is also shared genetic liability: ADHD shares heritability with autism, depression, anxiety, and substance use disorders. In the NCS-A, 69.5% of adolescents with ADHD had at least one comorbid mental health condition versus 40.8% of peers.
If I have anxiety, do I really have ADHD?
Possibly both. Anxiety and ADHD overlap on restlessness, distractibility, difficulty concentrating, and sleep disturbance. The distinguishing features are developmental course (ADHD predates the anxiety and is present in low-demand settings) and the nature of attention failure (ADHD attention drifts to whatever is more interesting; anxious attention narrows onto threat). In adults, 25-50% of those with ADHD also meet criteria for an anxiety disorder, and in many cases both diagnoses are correct.
Can stimulants treat both ADHD and depression?
Stimulants are not first-line treatment for major depressive disorder, but they often improve ADHD-related demoralization that is sometimes mistaken for depression. For true comorbid MDD plus ADHD, the standard sequence is to stabilize the depression first - typically with an SSRI or SNRI plus psychotherapy - and then treat residual ADHD. Bupropion has modest activity on both conditions.
Should I treat depression or ADHD first?
Treat the most acute or dangerous condition first. Active suicidality, severe MDD, active substance use, untreated psychosis, severe sleep apnea, and active mania all take priority over ADHD. Once those are stabilized, residual ADHD is addressed. The exception is when severe untreated ADHD is clearly driving the comorbid condition - then treating ADHD can produce rapid functional improvement.
Is autism plus ADHD one condition or two?
Two conditions that frequently co-occur. DSM-5 (2013) explicitly allows dual diagnosis. In pediatric autism samples, 30-80% meet criteria for comorbid ADHD; in pediatric ADHD samples, 15-25% meet criteria for autism. Dual-diagnosed children typically require treatment plans that address both - ADHD pharmacotherapy plus autism-focused behavioral support.
What conditions look like ADHD but are not?
Obstructive sleep apnea, hyperthyroidism, hearing impairment, uncorrected vision problems, lead exposure, severe psychosocial adversity, trauma, generalized anxiety, depression, and substance use can all produce ADHD-like attention problems. A careful evaluation screens for these before or alongside diagnosing ADHD.
Can sleep apnea be mistaken for ADHD?
Yes, particularly in children, who present with paradoxical hyperactivity rather than overt drowsiness. Approximately 33% of ADHD patients have a comorbid sleep disorder; a meaningful subset of children referred for ADHD evaluation turn out to have OSA. Screening for snoring, witnessed apneas, mouth breathing, enlarged tonsils, and morning headaches is essential.
Does treating ADHD fix learning disorders like dyslexia?
No. Learning disorders and ADHD are separate conditions that frequently co-occur. ADHD medication improves sustained attention to academic tasks, which helps a student get more out of reading remediation, but it does not remediate the underlying phonological processing deficit in dyslexia or the numerical cognition deficit in dyscalculia. Both conditions require their own evidence-based treatment.
18. Primary references
- Sultan RS, Liu SM, Hacker KA, Olfson M. Adolescents With Attention-Deficit/Hyperactivity Disorder: Adverse Behaviors and Comorbidity. J Adolesc Health. 2021;68(2):284-291. doi:10.1016/j.jadohealth.2020.09.036
- Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. doi:10.1176/ajp.2006.163.4.716
- Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001;40(2):147-158. doi:10.1097/00004583-200102000-00009
- MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086. doi:10.1001/archpsyc.56.12.1073
- Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385(9983):2190-2196. doi:10.1016/S0140-6736(14)61684-6
- Leitner Y. The co-occurrence of autism and attention deficit hyperactivity disorder in children - what do we know? Front Hum Neurosci. 2014;8:268. doi:10.3389/fnhum.2014.00268
- Cortese S, Faraone SV, Konofal E, Lecendreux M. Sleep in children with attention-deficit/hyperactivity disorder: meta-analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry. 2009;48(9):894-908. doi:10.1097/CHI.0b013e3181ac09c9
- Wilens TE, Martelon M, Joshi G, et al. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry. 2011;50(6):543-553. doi:10.1016/j.jaac.2011.01.021
- Quinn PD, Chang Z, Hur K, et al. ADHD medication and substance-related problems. Am J Psychiatry. 2017;174(9):877-885. doi:10.1176/appi.ajp.2017.16060686
- Tourette Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527-536. doi:10.1212/WNL.58.4.527
- Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24(4):562-575. doi:10.1038/s41380-018-0070-0
- Sciberras E, Mulraney M, Silva D, Coghill D. Prenatal risk factors and the etiology of ADHD - review of existing evidence. Curr Psychiatry Rep. 2017;19(1):1. doi:10.1007/s11920-017-0753-2
19. Further reading: cluster 6 spokes and adjacent clusters
Comorbidity & differential diagnosis (Cluster 6)
- ADHD vs Anxiety: How to Tell the Difference
- ADHD vs Autism: Differential Diagnosis
- OCD and ADHD: Comorbidity and Treatment
- Depression vs ADHD: Distinguishing the Two
- ADHD and Anxiety: The Connection
- ADHD and Sleep
- ADHD vs Sleep Apnea
- ADHD, Tic Disorders, Tourette, and Stimulants
- ADHD and Eating Disorders: Binge and Restrictive
- Cannabis and ADHD: The Risk Profile
- ADHD and Substance Use
Adjacent clusters and pillar pages
Considering a comprehensive ADHD evaluation?
Dr. Sultan provides ADHD evaluation and pharmacologic management at Columbia University Medical Center in New York City. Comorbidity-aware assessment is the standard of care - particularly for adults presenting for first-time evaluation.
Request Consultation Read: Pharmacology & Natural CourseAbout Dr. Ryan Sultan
Dr. Ryan Sultan is Assistant Professor of Clinical Psychiatry at Columbia University Irving Medical Center, Director of the Sultan Lab for Mental Health Informatics, and double board-certified in Adult Psychiatry and Child & Adolescent Psychiatry. He is an expert in ADHD psychopharmacology - including prescribing to children and adolescents - and has authored the field's most-cited recent work on the population-level comorbidity burden of ADHD and the protective effects of pharmacotherapy on real-world outcomes.
His 2021 Journal of Adolescent Health analysis of the National Comorbidity Survey Adolescent Supplement quantified the comorbidity burden of ADHD in a nationally representative U.S. sample, finding that 69.5% of adolescents with ADHD met criteria for at least one additional mental health condition. He holds an NIH NIDA K12 award and is the senior author of the 2019 JAMA Network Open study on antipsychotic use in youth with ADHD (440+ citations) and the 2025 JAMA Psychiatry editorial on the protective effects of ADHD medication.
Work With Dr. Sultan on Complex ADHD
Dr. Ryan S. Sultan, MD evaluates and treats ADHD with overlapping anxiety, depression, autism, OCD, sleep apnea, bipolar disorder, substance use, and trauma at Integrative Psych in Chelsea, Manhattan. Comorbid presentations are the rule, not the exception — and they reward the kind of structured, comorbidity-aware evaluation summarized on this page.
What sets Dr. Sultan's practice apart: Double board certification in Adult Psychiatry and Child & Adolescent Psychiatry. Active NIH NIDA-funded ADHD research at Columbia. 440+ research citations. Director of the Sultan Lab for Mental Health Informatics. Author of the 2019 JAMA Network Open study (Sultan, Liu, Hacker, Olfson; 440+ citations) that quantified the prescribing pattern around ADHD comorbidity, and the 2025 JAMA Psychiatry analysis (Sultan, Saunders, Veenstra-VanderWeele) of real-world outcomes.
The lineage of comorbidity research: The modern framework rests on Barkley's behavioral inhibition theory, the comorbidity work of Biederman and Wilens at Mass General, the pharmacoepidemiology of Olfson at Columbia, and — currently — the population-to-individual translation now underway at the Sultan Lab. The differential framework on this page is the public extension of that active NIH research program.